Showing results (21-30 of 47) with videos related to
Sort By:
Pageof 5
Journal of Clinical Pharmacology|May 21, 2008
Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulationJeffrey S Barrett, Jun Shi, Hai-Tang Xie, et al.Journal of Clinical Pharmacology|February 3, 2018
Oliceridine, a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic ModelMichael J Fossler, Brian M Sadler, Colm Farrell, et al.Journal of Clinical Pharmacology|February 8, 2018
Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic ModelMichael J Fossler, Brian M Sadler, Colm Farrell, et al.Clinical Drug Investigation|June 26, 2020
Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative PainSabry Ayad, Mark A Demitrack, David A Burt, et al.Journal of Clinical Pharmacology|August 20, 2004
Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary interventionDonna S Cox, Neal S Kleiman, Duane A Boyle, et al.Anesthesiology|August 14, 2020
Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus MorphineAlbert Dahan, C Jan van Dam, Marieke Niesters, et al.Thrombosis and Haemostasis|June 1, 2002
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic studyJames W Hainer, Jeffrey S Barrett, Christopher A Assaid, et al.Pain and Therapy|August 5, 2021
Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled TrialsGregory B Hammer, Ashish K Khanna, Cathy Michalsky, et al.CNS Drugs|July 18, 2020
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy SubjectsMichael J Fossler, Virginia Schmith, Stephen A Greene, et al.British Journal of Clinical Pharmacology|March 31, 2015
Treatment of spontaneous preterm labour with retosiban: a phase 2 proof-of-concept studySteven Thornton, Hugh Miller, Guillermo Valenzuela, et al.Pageof 5